MedTrace Logo

Ga-68 FAPI PET Before Immunotherapy

NCT06451536 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-06-11

No results posted yet for this study

Summary

It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

Conditions

  • Mesotheliomas Pleural

Interventions

DIAGNOSTIC_TEST

Ga-68 FAPI PET/CT

imaging of FAP expression of tumor before immunotherapy

Sponsors & Collaborators

  • Liv Hospital Ankara

    collaborator OTHER

  • Social Sciences University of Ankara

    collaborator OTHER

  • Ankara Yildirim Beyazıt University

    collaborator OTHER

  • Ankara University

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06451536 on ClinicalTrials.gov